Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate.
A reversed-phase high-performance liquid chromatographic assay for the simultaneous determination of phenytoin and fosphenytoin, a prodrug for phenytoin, in human plasma and plasma ultrafiltrate is described. For plasma, the method involves simple extraction of drugs with diethyl ether and evaporation of solvent, followed by injection of the reconstituted sample onto a reversed-phase C18 column. Plasma ultrafiltrate is injected directly into the HPLC column. Compounds are eluted using an ion-pair mobile phase containing 20% acetonitrile. The eluent is monitored by UV absorbance at 210 nm. The fosphenytoin standard curves are linear in the concentration range 0.4 to 400 microg/ml for plasma and 0.03 to 80 microg/ml for ultrafiltrate. Phenytoin standard curves are linear from 0.08 to 40 microg/ml for plasma and from 0.02 to 5.0 microg/ml for ultrafiltrate. No interferences with the assay procedure were found in drug-free blank plasma or plasma ultrafiltrate. Relative standard deviation for replicate plasma or ultrafiltrate samples was less than 5% at concentrations above the limit of quantitation for both within- and between-run calculations.
Cwik
M J
MJ
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612, USA.
Liang
M
M
Deyo
K
K
Andrews
C
C
Fischer
J
J
D000927:Anticonvulsants / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D010672:Phenytoin / Q000031:analogs & derivatives* / Q000097:blood*; D011355:Prodrugs / Q000032:analysis*; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet
D000927:Anticonvulsants; D011355:Prodrugs; D010672:Phenytoin; C043114:fosphenytoin